Akari Therapeutics Plc (AKTX)
11.30
+0.42
(+3.86%)
USD |
NASDAQ |
Sep 11, 16:00
11.92
+0.62
(+5.49%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value : 12.72M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 12.72M |
| September 10, 2026 | 11.98M |
| September 09, 2026 | 11.44M |
| September 08, 2026 | 12.12M |
| September 04, 2026 | 13.02M |
| September 03, 2026 | 11.91M |
| September 02, 2026 | 10.71M |
| September 01, 2026 | 11.09M |
| August 31, 2026 | 11.20M |
| August 28, 2026 | 11.67M |
| August 27, 2026 | 8.710M |
| August 26, 2026 | 8.868M |
| August 25, 2026 | 6.715M |
| August 24, 2026 | 6.014M |
| August 21, 2026 | 6.680M |
| August 20, 2026 | 6.575M |
| August 19, 2026 | 6.767M |
| August 18, 2026 | 6.765M |
| August 17, 2026 | 6.102M |
| August 14, 2026 | 6.137M |
| August 13, 2026 | 5.192M |
| August 12, 2026 | 5.507M |
| August 11, 2026 | 6.470M |
| August 10, 2026 | 6.120M |
| August 07, 2026 | 5.192M |
| Date | Value |
|---|---|
| August 06, 2026 | 7.082M |
| August 05, 2026 | 6.067M |
| August 04, 2026 | 6.575M |
| August 03, 2026 | 5.822M |
| July 31, 2026 | 6.697M |
| July 30, 2026 | 6.942M |
| July 29, 2026 | 7.380M |
| July 28, 2026 | 7.695M |
| July 27, 2026 | 7.747M |
| July 24, 2026 | 8.168M |
| July 23, 2026 | 9.218M |
| July 22, 2026 | 10.11M |
| July 21, 2026 | 9.209M |
| July 20, 2026 | 11.60M |
| July 17, 2026 | 12.21M |
| July 16, 2026 | 13.07M |
| July 15, 2026 | 14.07M |
| July 14, 2026 | 16.43M |
| July 13, 2026 | 16.39M |
| July 10, 2026 | 17.23M |
| July 09, 2026 | 15.97M |
| July 08, 2026 | 17.81M |
| July 07, 2026 | 20.04M |
| July 06, 2026 | 12.02M |
| July 02, 2026 | 11.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 488.42M |
| Cellectis SA | 249.60M |
| argenx SE | 60.85B |
| Autolus Therapeutics Plc | 665.07M |
| Evaxion AS | 19.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.816M |
| Total Expenses (Quarterly) | 4.816M |
| EPS Diluted (Quarterly) | -2.404 |
| Earnings Yield | -175.0% |